Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice

NeuroReport

Volumn 20, Issue 5, 2009, Pages 482-486

  Kirchhoff, Jeppe ^a   Mørk, Arne ^a   Brennum, Lise T ^a   Sager, Thomas N ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; 3,4 dihydroxy L phenylalanine; Dopamine; In vivo microdialysis; Parkinson's disease; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE; DOPAMINE; DOPAMINE 2 RECEPTOR; LEVODOPA; RACLOPRIDE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROTOXIN; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; EXTRACELLULAR MATRIX; IN VIVO STUDY; INTOXICATION; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DRUG EFFECT; EXTRACELLULAR SPACE; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; EXTRACELLULAR SPACE; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; NEUROTOXINS; RACLOPRIDE; RECEPTORS, DOPAMINE D2; TRITIUM;

EID: 63849206689     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32832984d6     Document Type: Article

References (18)

1. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 2003; 17:729-762.
2. Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R. Peculiarities of L-DOPA treatment of Parkinson's disease. Amino Acids 2005; 28:157-164.
3. Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001; 2:325-334.
4. Willis GL, Donnan GA. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 1987; 402:269-274.
5. Meredith GE, Kang UJ. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 2006; 21:1595-1606.
6. Tillerson JL, Miller GW. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J Neurosci Methods 2003; 123:189-200.
7. Tillerson JL, Caudle WM, Reveron ME, Miller GW. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 2002; 178:80-90.
8. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 1985; 50:435-441.
9. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 1998; 83:165-175.
10. Franklin KBJ, Paxinos G. The mouse brain. San Diego, California: Academic Press; 1997.
11. Andersen PH, Nielsen EB, Gronvald FC, Braestrup C. Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo. Eur J Pharmacol 1986; 120:143-144.
12. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003; 305:625-631.
13. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150:76-85.
14. Boulet S, Mounayar S, Poupard A, Bertrand A, Jan C, Pessiglione M, et al. Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J Neurosci 2008; 28:9575-9584.
15. Elsworth JD, Taylor JR, Sladek JR Jr, Collier TJ, Redmond DE Jr, Roth RH. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 2000; 95:399-408.
16. Obeso JA, Rodriguez-Oroz MC, Itez-Temino B, Blesa FJ, Guridi J, Marin C, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord 2008; 23 (Suppl 3):S548-S559.
17. Tanji H, Araki T, Nagasawa H, Itoyama Y. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. Brain Res 1999; 824:224-231.
18. Ishiwata K, Koyanagi Y, Abe K, Kawamura K, Taguchi K, Saitoh T, et al. Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism- preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum. J Neurochem 2001; 79:868-876.